Six Cancer Therapies Move Toward Broader EU Use

https://www.medscape.com/viewarticle/six-cancer-therapies-move-toward-broader-eu-use-2026a1000z9g?ecd=WNL_trdalrt_pos1_ous_260923_etid8720513&uac=148436CN&impID=8720513 The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended indication extensions for six already authorized oncology and hematology medicines at its September 2026 meeting. Abiraterone Mylan (abiraterone acetate; Mylan Pharmaceuticals Limited), Enhertu (trastuzumab deruxtecan; Daiichi Sankyo/AstraZeneca), Keytruda (pembrolizumab; Merck Sharp & Dohme), Padcev (enfortumab vedotin; Astellas Pharma), Pepaxti (melphalan flufenamide; Oncopeptides AB), and Tecvayli (teclistamab; Janssen-Cilag International) were all backed for broader use, either by moving into earlier treatment settings or expanding the eligible patient population.